Inmune Bio, INC DEF 14A proxy statements

INmune Bio Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors, ratify auditors, and approve an updated stock incentive plan.

INmune Bio Inc. is seeking stockholder approval to reprice certain outstanding stock options for current directors, executive officers, and employees to address retention and competitiveness concerns.

INmune Bio Inc. has dismissed Marcum LLP and appointed CBIZ CPAs as their new independent registered public accounting firm, leading to an amendment of the proxy statement and a rescheduling of the annual meeting.

INmune Bio Inc. files a supplement to its proxy statement to correct a typographical error concerning the voting standard for the approval of the Second Amended and Restated 2021 Stock Incentive Plan.

INmune Bio Inc. will hold its annual stockholder meeting virtually on May 28, 2025, to vote on the election of directors, ratification of the accounting firm, executive compensation, and approval of the Second Amended and Restated 2021 Stock Incentive Plan.

INmune Bio Inc. will hold its annual stockholders meeting virtually on July 19, 2024, to elect directors and ratify the appointment of its independent accounting firm.